Treat the indicated condition, not a marketing promise
Some GLP-1 receptor agonists and related incretin medicines are approved for type 2 diabetes, chronic weight management, or other labeled indications. Obesity is associated with increased risk of several cancers, but that association does not prove that a GLP-1 medicine prevents a particular cancer or recurrence.
The decision should consider the exact drug and indication, medical history, other medicines, nutrition, muscle mass, bone health, gastrointestinal effects, gallbladder and pancreatic history, kidney risks, pregnancy plans, and the product’s current prescribing information.
Surgery changes the medication conversation
Because these medicines can delay gastric emptying, the prescriber, surgeon, and anesthesia team need an explicit perioperative plan. Do not stop or continue a prescription based on a generic website schedule; recommendations can change and must reflect symptoms, dose escalation, procedure, fasting instructions, and anesthesia risk.
Rapid weight loss before reconstruction may also affect nutrition, muscle, wound healing, body composition, flap planning, and implant or aesthetic goals. The plan should define a safe pace and a protein, resistance-training, and monitoring strategy.
Microdosing, alcohol, and movement
“Microdosing” GLP-1 medication is not a standard FDA-approved dosing framework. Splitting pens, using unapproved products, or improvising doses can create sterility, accuracy, quality, and safety risks. A licensed prescriber should use an approved product and evidence-based schedule or clearly explain any off-label approach.
Alcohol causes cancer, including breast cancer; drinking less or not at all lowers exposure. Physical activity is associated with lower risk of several cancers and supports strength, function, metabolic health, and recovery. Exercise should be adapted to current treatment, anemia, neuropathy, bone disease, lymphedema risk, and postoperative restrictions.